Kiadis Pharma appoints Jeroen Rovers as its Chief Medical Officer

Clinical and Business Development expert re-joins the Company

Amsterdam, The Netherlands, September 3, 2014 – Kiadis Pharma B.V. (“Kiadis Pharma”, “Kiadis” or “the Company”), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing T-cell immunother­a­py treat­ments for blood can­cers, today announces the appoint­ment of Dr. Jeroen Rovers, MD PhD, as its Chief Medical Officer. Jeroen Rovers was most recent­ly Chief Medical Officer at Ceronco Biosciences. Prior to that he was VP Medical Affairs at Kiadis Pharma and has remained a con­sul­tant to the Company until his re-appoint­ment on September 1, 2014. Jeroen worked at Organon (acquired by Schering – Plough in 2007) between 2005-2008, lat­ter­ly as Director of Clinical Development and Business Development. Jeroen has more than 15 years of pro­fes­sion­al expe­ri­ence in clin­i­cal devel­op­ment with­in acad­e­mia and the phar­ma­ceu­ti­cal indus­try. He has a strong back­ground in cell based ther­a­peu­tic­s/ad­vanced-ther­a­py med­i­c­i­nal prod­ucts (ATMPs) and has a wealth of expe­ri­ence in oncol­o­gy, hema­tol­ogy and oth­er immunol­o­gy-relat­ed fields such as organ trans­plan­ta­tion.
Jeroen has sig­nif­i­cant expe­ri­ence in con­duct­ing clin­i­cal tri­als in var­i­ous oncol­o­gy indi­ca­tions cov­er­ing all phas­es of the clin­i­cal devel­op­ment path­way (Phase I to III), hav­ing coor­di­nat­ed clin­i­cal tri­als in the EU for var­i­ous phar­ma­ceu­ti­cal com­pa­nies. He has also been involved in ear­ly and lat­er stage devel­op­ment of can­cer immune ther­a­pies and con­duct­ed his doc­tor­al the­sis on the use of light-acti­vat­ed drugs in the treat­ment of tumors.
Manfred Ruediger, PhD, Chief Executive Officer of Kiadis Pharma, com­ment­ed: “Jeroen joins Kiadis with a deep knowl­edge and clear under­stand­ing of ATIR™ and of the poten­tial of its under­ly­ing tech­nol­o­gy plat­form. I am delight­ed to wel­come him as a key mem­ber of our Executive Management Team at Kiadis at this impor­tant time for the Company. His med­ical and clin­i­cal exper­tise, cou­pled with busi­ness devel­op­ment con­nec­tions, will be extreme­ly use­ful giv­en the stage of our Phase II pro­gram and the inter­est we have been see­ing in our field. We feel he will con­tin­ue to make a valu­able addi­tion to our team and help us to make ATIR™ a real­i­ty for patients and to devel­op it to its full poten­tial. On behalf of the team and our Board of Directors we wish to thank Edwin Wagena, Chief Development Officer, for his con­tri­bu­tion to Kiadis in the ear­li­er stages since 2008 and wish him all suc­cess in his future career.”
Jeroen Rovers, Chief Medical Officer, added: “I am extreme­ly excit­ed to have the oppor­tu­ni­ty to rejoin Kiadis Pharma and be able to focus on its T-cell based immunother­a­py prod­uct ATIR™, which has the poten­tial to enable safe and effi­ca­cious use of par­tial­ly mis­matched (hap­loiden­ti­cal) fam­i­ly mem­bers as donors for patients suf­fer­ing from hema­to­log­ic malig­nan­cies such as acute myeloid leukemia (AML) and acute lym­phoblas­tic leukemia (ALL). All patients in need of a stem cell donor, whether after con­ven­tion­al treat­ments or inno­v­a­tive approach­es like Chimeric Antigen Receptor (CAR) T-cell ther­a­pies, will poten­tial­ly ben­e­fit from ATIR™. I believe ATIR™ is a tru­ly inno­v­a­tive prod­uct and has the poten­tial to become a key part of the next gen­er­a­tion treat­ments of blood can­cers.”

Leave a Reply

Your email address will not be published. Required fields are marked *